Survival with cemiplimab in recurrent cervical cancer

Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1-blocking antibody approved to treat lung and skin cancers, has been shown to have preliminary clinical activity in this population. The multinational phase 3 study EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 compared cemiplimab with single-agent chemotherapy for recurrent cervical cancer after first-line platinum-containing chemotherapy. The median overall survival was significantly longer with cemiplimab than with chemotherapy (12.0 versus 8.5 months; HR 0.69; p<0.001).